Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 32INDUSTRY 23NIH 5NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 4Sarcoma 3Breast 3Thoracic 2Gynecologic 2Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Endocrine 1

Conditions

Somatostatinoma 1Insulinoma 1Glucagonoma 1Gastrinoma 1Carcinoma, Islet Cell 1

Interventions

Filgrastim 3Doxorubicin 3Temozolomide 2Octreotide 2Ifosfamide 2Etoposide 2Cisplatin 2Capecitabine 2vatalanib 1vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1telotristat ethyl 1pegfilgrastim 1motesanib diphosphate 1mercaptoundecahydrododecaborate 1lanreotide 1batifiban 1Suramin 1Radiotherapy 1Platinum 1Mitotane 1Hydrocortisone 1Granulocyte Colony-Stimulating Factor 1Gene Expression Profiling 1Everolimus 1Ethane 1Docetaxel 1Dichlorodiphenyldichloroethane 1DNA Methylation 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Everolimus × Endocrine × Clear all
NCT02031536 2023-06-29

Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery

Eastern Cooperative Oncology Group

Phase 2 Terminated
2 enrolled 8 charts
Endocrine

Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡